University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Med Phys. 2023 Jun;50 Suppl 1:74-79. doi: 10.1002/mp.16100. Epub 2022 Dec 2.
Arguably, intensity-modulated radiotherapy (IMRT) is one of the most important contributions by physicists in medicine to the treatment of cancer. It enabled the achievement of dose distributions that allowed treatment of targets to high doses and yet spared normal tissues to degrees previously considered virtually impossible. The concept underlying IMRT for photons, originally called "inverse planning," was introduced by Anders Brahme in the early 1980s. Since then, many physicists have been conducting research to advance the state of the art, to overcome obstacles discovered and to develop tools and techniques to translate it clinically. IMRT was first implemented clinically the early 1990's. Soon thereafter, it was also incorporated into intensity modulated particle therapy (IMPT), initially for protons and eventually for ions heavier than protons.
In IMRT, intensities of small segments or beamlets of multiple incident beams are optimized to produce the best approximation of desired dose distributions that deliver the requisite tumor dose and maximally spare normal tissues. Such dose distributions are delivered using dynamic multi-leaf collimators whose leaves move continuously while the radiation is on or in a step-and-shoot fashion. For IMPT, there is an extra degree of freedom, that of energies of particle beamlets, which are part of the optimization process. IMPT dose distributions allow substantial additional sparing of normal tissues. They are delivered using scanning beams.
IMRT and IMPT represents a true paradigm shift in the way cancer patients are treated. Their evolution, especially that of IMPT, is still ongoing, with new advancements being added continually. With the improving understanding of the immunomodulatory effects of radiotherapy, it is quite plausible that a combination of IMPT and immunotherapy will mature into one of the most effective ways of treating not just localized cancers but also systemic disease.
可以说,调强放疗(IMRT)是物理学家对癌症治疗最重要的贡献之一。它实现了剂量分布,使靶区能够接受高剂量治疗,同时又使正常组织免受以前认为几乎不可能的程度的损伤。最初被称为“逆向计划”的光子调强放疗的基本原理是由安德斯·布雷默(Anders Brahme)在 20 世纪 80 年代初提出的。从那时起,许多物理学家一直在进行研究,以推进该技术的发展,克服发现的障碍,并开发工具和技术将其转化为临床应用。IMRT 于 20 世纪 90 年代初首次在临床上实施。此后不久,它也被纳入强度调制粒子治疗(IMPT)中,最初是针对质子,最终是针对比质子重的离子。
在调强放疗中,多个入射光束的小片段或射束的强度被优化,以产生最佳的近似所需剂量分布,从而提供所需的肿瘤剂量,并最大限度地保护正常组织。这些剂量分布是通过使用动态多叶准直器来实现的,多叶准直器的叶片在辐射开启时连续移动,或者以步进和射击的方式移动。对于 IMPT,还有一个额外的自由度,即粒子射束的能量,这是优化过程的一部分。IMPT 剂量分布允许对正常组织进行大量额外的保护。它们是通过扫描束来实现的。
调强放疗和强度调制粒子治疗代表了癌症治疗方式的真正范式转变。它们的发展,特别是 IMPT 的发展,仍在继续,新的进展不断增加。随着对放疗免疫调节作用的认识不断提高,很有可能将 IMPT 与免疫疗法相结合,成为治疗局部癌症和全身疾病的最有效方法之一。